Insmed registers Phase 1 trial testing INS1033 in healthy volunteers
New study will examine safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of INS1033.
Insmed's only new registry item this week is a first-in-human trial for its investigational compound INS1033.
- Insmed registered NCT07765706, titled "A Phase 1, Randomized, Double-blind, Placebo-controlled, 2-Part Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of INS1033 in Healthy Participants."1 The study is not yet recruiting, with an estimated start of August 25, 2026, and plans to enroll 116 participants1 to test single and multiple ascending doses of the drug against placebo.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.